Related Experiment Video

Updated: Apr 15, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.6K

Potent effects of dioscin against liver fibrosis

Xiaoling Zhang1, Xu Han1, Lianhong Yin1

  • 1College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China.

Scientific Reports
|April 9, 2015
PubMed

Insights

Dioscin effectively combats liver fibrosis by inhibiting hepatic stellate cell activation and promoting apoptosis. This natural compound modulates key fibrotic pathways, offering a promising therapeutic candidate for liver fibrosis treatment.

Area of Science:

  • Pharmacology
  • Hepatology
  • Molecular Biology

Background:

  • Liver fibrosis is a significant health concern with limited treatment options.
  • Dioscin's potential in liver injury was previously noted, but its anti-fibrotic effects were unexplored.

Purpose of the Study:

  • To investigate the anti-fibrotic activities of dioscin.
  • To elucidate the underlying molecular mechanisms of dioscin's action against liver fibrosis.

Main Methods:

  • In vitro studies using hepatic stellate cells (HSCs) and hepatocytes.
  • In vivo studies involving animal models of liver fibrosis.
  • Analysis of key fibrotic markers, signaling pathways (TGF-β1/Smad, Wnt/β-catenin, MAPK, mitochondrial), oxidative stress, and inflammation.

Main Results:

  • Dioscin inhibited viability and activation of HSCs, inducing apoptosis.
  • Dioscin upregulated peroxisome proliferator activated receptor-γ (PPAR-γ) and downregulated α-SMA, TGF-β1, COL1A1, and COL3A1.
  • In vivo, dioscin improved liver function, reduced fibrosis markers, and attenuated oxidative stress and inflammation.

Conclusions:

  • Dioscin demonstrates potent anti-fibrotic effects by targeting multiple pathways and promoting HSC senescence.
  • Dioscin facilitates matrix degradation and exhibits hepatoprotective properties.
  • Dioscin represents a promising novel therapeutic candidate for liver fibrosis.

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

55.4K
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat09:27

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

12.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
5.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
356